JP2021525059A5 - - Google Patents
Info
- Publication number
- JP2021525059A5 JP2021525059A5 JP2020558493A JP2020558493A JP2021525059A5 JP 2021525059 A5 JP2021525059 A5 JP 2021525059A5 JP 2020558493 A JP2020558493 A JP 2020558493A JP 2020558493 A JP2020558493 A JP 2020558493A JP 2021525059 A5 JP2021525059 A5 JP 2021525059A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- seq
- isolated antibody
- represented
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024014317A JP7798931B2 (ja) | 2018-04-30 | 2024-02-01 | カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664882P | 2018-04-30 | 2018-04-30 | |
| US62/664,882 | 2018-04-30 | ||
| PCT/IB2019/000503 WO2019211665A1 (en) | 2018-04-30 | 2019-04-29 | Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014317A Division JP7798931B2 (ja) | 2018-04-30 | 2024-02-01 | カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021525059A JP2021525059A (ja) | 2021-09-24 |
| JP2021525059A5 true JP2021525059A5 (https=) | 2022-05-11 |
| JPWO2019211665A5 JPWO2019211665A5 (https=) | 2022-05-11 |
| JP7431750B2 JP7431750B2 (ja) | 2024-02-15 |
Family
ID=67396963
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558493A Active JP7431750B2 (ja) | 2018-04-30 | 2019-04-29 | カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用 |
| JP2024014317A Active JP7798931B2 (ja) | 2018-04-30 | 2024-02-01 | カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014317A Active JP7798931B2 (ja) | 2018-04-30 | 2024-02-01 | カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US12202901B2 (https=) |
| EP (1) | EP3787746A1 (https=) |
| JP (2) | JP7431750B2 (https=) |
| KR (1) | KR20210005051A (https=) |
| CN (1) | CN112218684A (https=) |
| AR (1) | AR114436A1 (https=) |
| AU (1) | AU2019264029A1 (https=) |
| BR (1) | BR112020022035A2 (https=) |
| CA (1) | CA3098416A1 (https=) |
| CL (1) | CL2020002793A1 (https=) |
| CO (1) | CO2020014681A2 (https=) |
| EA (1) | EA202092593A1 (https=) |
| EC (1) | ECSP20076576A (https=) |
| IL (1) | IL278276B1 (https=) |
| MA (1) | MA52504A (https=) |
| MX (1) | MX2020011498A (https=) |
| PE (1) | PE20210419A1 (https=) |
| PH (1) | PH12020551805A1 (https=) |
| SG (1) | SG11202010388SA (https=) |
| TW (1) | TWI882957B (https=) |
| WO (1) | WO2019211665A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3098416A1 (en) | 2018-04-30 | 2019-11-07 | Takeda Pharmaceutical Company Limited | Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof |
| EP4504792A4 (en) * | 2022-04-04 | 2026-04-15 | Bird Rock Bio Sub Inc | PREDICTION AND TREATMENT OF RAPIDLY PROGRESS KIDNEY DISEASE |
| JPWO2023234406A1 (https=) | 2022-06-03 | 2023-12-07 | ||
| WO2023242843A1 (en) * | 2022-06-17 | 2023-12-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Peripheralization of centrally-acting cannabinoid-1 receptor antagonists by nanoparticles for the treatment metabolic related conditions |
| WO2024022478A1 (zh) * | 2022-07-28 | 2024-02-01 | 长春金赛药业有限责任公司 | 结合大麻素受体cb1的抗体及其用途 |
| WO2025257151A1 (en) * | 2024-06-10 | 2025-12-18 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for treating ciliopathies |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5006309A (en) | 1988-04-22 | 1991-04-09 | Abbott Laboratories | Immunoassay device with liquid transfer between wells by washing |
| US5089424A (en) | 1988-06-14 | 1992-02-18 | Abbott Laboratories | Method and apparatus for heterogeneous chemiluminescence assay |
| US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
| CA2069530A1 (en) | 1991-06-03 | 1992-12-04 | Cass J. Grandone | Reagent pack for immunoassays |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
| US20040018577A1 (en) | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
| WO2005023232A2 (en) | 2003-09-04 | 2005-03-17 | Affibody Ab | Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders. |
| US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
| US7682833B2 (en) | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| PE20100092A1 (es) | 2008-06-03 | 2010-03-12 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
| AU2014302410B2 (en) | 2013-06-26 | 2019-06-13 | Amgen Inc. | CB1 receptor antigen-binding proteins and uses thereof |
| MA39708A (fr) | 2014-03-27 | 2021-03-31 | Bird Rock Bio Inc | Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain |
| US10277406B1 (en) * | 2014-09-05 | 2019-04-30 | Digicert, Inc. | Authentication process for issuing sequence of short-lived digital certificates |
| US10034865B2 (en) | 2015-09-10 | 2018-07-31 | Kashiv Pharma, Llc | Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof |
| BR112018006633A2 (en) * | 2015-09-30 | 2018-10-23 | Bird Rock Bio, Inc. | antibodies that bind to human cannabinoid receptor 1 (cb1) |
| US20190240293A1 (en) | 2016-07-26 | 2019-08-08 | Flagship Pioneering Innovations V, Inc. | Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response |
| CA3098416A1 (en) | 2018-04-30 | 2019-11-07 | Takeda Pharmaceutical Company Limited | Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof |
-
2019
- 2019-04-29 CA CA3098416A patent/CA3098416A1/en active Pending
- 2019-04-29 EP EP19742647.1A patent/EP3787746A1/en active Pending
- 2019-04-29 BR BR112020022035-3A patent/BR112020022035A2/pt unknown
- 2019-04-29 KR KR1020207032056A patent/KR20210005051A/ko active Pending
- 2019-04-29 CN CN201980029451.9A patent/CN112218684A/zh active Pending
- 2019-04-29 MX MX2020011498A patent/MX2020011498A/es unknown
- 2019-04-29 EA EA202092593A patent/EA202092593A1/ru unknown
- 2019-04-29 AR ARP190101123A patent/AR114436A1/es unknown
- 2019-04-29 MA MA052504A patent/MA52504A/fr unknown
- 2019-04-29 SG SG11202010388SA patent/SG11202010388SA/en unknown
- 2019-04-29 AU AU2019264029A patent/AU2019264029A1/en active Pending
- 2019-04-29 PE PE2020001750A patent/PE20210419A1/es unknown
- 2019-04-29 IL IL278276A patent/IL278276B1/en unknown
- 2019-04-29 US US17/052,048 patent/US12202901B2/en active Active
- 2019-04-29 JP JP2020558493A patent/JP7431750B2/ja active Active
- 2019-04-29 WO PCT/IB2019/000503 patent/WO2019211665A1/en not_active Ceased
- 2019-04-30 TW TW108115125A patent/TWI882957B/zh active
-
2020
- 2020-10-27 CL CL2020002793A patent/CL2020002793A1/es unknown
- 2020-10-29 PH PH12020551805A patent/PH12020551805A1/en unknown
- 2020-11-26 CO CONC2020/0014681A patent/CO2020014681A2/es unknown
- 2020-11-27 EC ECSENADI202076576A patent/ECSP20076576A/es unknown
-
2021
- 2021-03-16 US US17/203,291 patent/US11746155B2/en active Active
-
2024
- 2024-02-01 JP JP2024014317A patent/JP7798931B2/ja active Active
-
2025
- 2025-01-14 US US19/019,913 patent/US20250250341A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525059A5 (https=) | ||
| JP2019530434A5 (https=) | ||
| JP2014509861A5 (https=) | ||
| JP2023134618A5 (https=) | ||
| CN115698079A (zh) | 抗cd79b抗体药物偶联物、其制备方法及其医药用途 | |
| JP2021520825A5 (https=) | ||
| JP2021530960A5 (https=) | ||
| JP2015509947A5 (https=) | ||
| JP2021534797A5 (https=) | ||
| JP2016503067A5 (https=) | ||
| JP2010517513A5 (https=) | ||
| JP2016505546A5 (https=) | ||
| AU2014248636B2 (en) | Humanized anti-N2 antibodies | |
| WO2019195313A1 (en) | Anti-vegf antagonist and pedf agonist constructs and uses thereof | |
| JP2018522540A5 (https=) | ||
| CA3096791C (en) | Cell engaging binding molecules | |
| JP2013521252A5 (https=) | ||
| CN118475367A (zh) | 用于治疗和预防covid-19的组合物 | |
| TW202523696A (zh) | 抗-幹細胞因子抗體及其使用方法 | |
| JPWO2020014617A5 (https=) | ||
| JP2023537078A (ja) | ＣＯＶＩＤ－１９を治療及び防止するためのＳＡＲＳ－ＣｏＶ－２抗体 | |
| JPWO2019197675A5 (https=) | ||
| JPWO2019211665A5 (https=) | ||
| JPWO2020047374A5 (https=) | ||
| JPWO2021042019A5 (https=) |